Our Internal Data.

IRO demonstrated minimal variability with a coefficient of variation <5% for all sampling points

Achieved a transduced cell yield up to 3.5x higher than the control, ranging from 1.1 – 3.5 billion transduced cells on day 7

Demonstrated significantly higher transduction efficiency vs. the control (MOI: 0.5)

Achieves a maximum cell yield up to 2.5x higher than a widely used cell expansion system using the same raw materials (cells, cytokines, media, etc.)

Consistently reaches 1-2B total cells in 4-6 days and can achieve 10-12B cells in 10 days, maintaining >95% viability

Delivers high quality T cells with a desirable T cell memory phenotype and no evidence of exhaustion

The Ori platform has delivered more than 2 billion CD19 CAR-T cells in 7 days and up to 4 billion CD19 CAR-T cells in a 9-day process

Delivers high quality T cells with a desirable T cell memory phenotype and comparable to the control

Produces functional CAR-T cells measured by cytokine release and killing assays after co-culturing with NALM6, a CD19-positive cancer cell line

Higher transduction efficiency was observed in Ori using an updated and optimised protocol compared to Control* across the tested Multiplicity of Infections (MOI) *A scale-down vessel (10x smaller) of a widely used cell expansion system was used as a control

Higher yield of CAR-T cells can be achieved in Ori platform using MOI 0.5 and 0.25 compared to an industry-standard platform (Control) using MOI 1.0. This demonstrates the possibility of reducing the virus needed to achieve a target CAR-T yield and ultimately reducing cost of goods

After 3 weeks of tech transfer, our partner ran 3 CD19 CAR-T runs on their site using 3 different donors and their CAR construct